Economics of Cancer Care
作者： James Khatcheressian , Thomas J. Smith
关键词: Process (engineering) 、 Business 、 Health care 、 Public economics 、 Quality of life (healthcare) 、 Limited resources 、 Clin oncol 、 Know-how 、 Task (project management)
摘要: Several major issues emerge when combining the “dismal science” of economics1 with science oncology. With rising healthcare costs yet limited resources, it becomes important to know how factor economic considerations into medical decision-making process. This task is made more difficult by paucity comparative studies and outcomes (under general term cost-effectiveness) quality life; as a result, clinicians are left on their own decide “who does what whom, at cost, whose money.”
springer.com
springerlink.com参考文章(63)
F Bochner, E D Martin, N G Burgess, A A Somogyi, G. M H Misan, How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital. BMJ. ,vol. 308, pp. 901- 905 ,(1994) , 10.1136/BMJ.308.6933.901
Gregory P Samsa, Amy P Abernethy, David B Matchar, A clinical decision and economic analysis model of cancer pain management. The American Journal of Managed Care. ,vol. 9, pp. 651- 664 ,(2003)
T J Smith, J N Bodurtha, Ethical considerations in oncology: balancing the interests of patients, oncologists, and society. Journal of Clinical Oncology. ,vol. 13, pp. 2464- 2470 ,(1995) , 10.1200/JCO.1995.13.9.2464
Bruce E. Hillner, Jane C. Weeks, Christopher E. Desch, Thomas J. Smith, Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis Journal of Clinical Oncology. ,vol. 18, pp. 72- 79 ,(2000) , 10.1200/JCO.2000.18.1.72
L Jaakkimainen, P J Goodwin, J Pater, P Warde, N Murray, E Rapp, Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. Journal of Clinical Oncology. ,vol. 8, pp. 1301- 1309 ,(1990) , 10.1200/JCO.1990.8.8.1301
A. Laupacis, D. Feeny, P. X. Tugwell, A. S. Detsky, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Canadian Medical Association Journal. ,vol. 146, pp. 473- 481 ,(1992)
J A Hayman, B E Hillner, J R Harris, J C Weeks, Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. Journal of Clinical Oncology. ,vol. 16, pp. 1022- 1029 ,(1998) , 10.1200/JCO.1998.16.3.1022
C.C. Earle, R.H. Chapman, C.S. Baker, C.M. Bell, P.W. Stone, E.A. Sandberg, P.J. Neumann, Systematic Overview of Cost-Utility Assessments in Oncology Journal of Clinical Oncology. ,vol. 18, pp. 3302- 3317 ,(2000) , 10.1200/JCO.2000.18.18.3302
D J Bloomfield, M D Krahn, T Neogi, T Panzarella, T J Smith, P Warde, A R Willan, S Ernst, M J Moore, A Neville, I F Tannock, Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 16, pp. 2272- 2279 ,(1998) , 10.1200/JCO.1998.16.6.2272
T J Smith, B E Hillner, The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. Journal of Clinical Oncology. ,vol. 11, pp. 771- 776 ,(1993) , 10.1200/JCO.1993.11.4.771